Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TOVX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTheriva Biologics reports Q1 2026 financial results in routine earnings disclosure
Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read
Key Changes
-
medium
Company issued press release with Q1 2026 financial results for quarter ended March 31, 2026. Actual financial figures are in the attached press release exhibit, not in the 8-K body itself.
Item 2.02 verify on EDGAR →
Summary
Theriva Biologics filed a routine 8-K on May 5, 2026 to announce its first quarter 2026 financial results. The filing references a press release dated the same day containing financial information for the quarter ended March 31, 2026, though the actual numbers appear only in the attached exhibit rather than in the filing body. This is a standard quarterly earnings announcement format commonly used by public companies to comply with disclosure requirements.
Investors should review the attached press release exhibit for the actual financial performance metrics, including revenue, expenses, cash position, and any forward-looking guidance management may have provided. Watch for the company's 10-Q filing in the coming weeks, which will provide complete financial statements and management discussion of Q1 results.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Theriva Biologics disclosed Q1 2026 financial results via press release on May 5, 2026.
Added in current filing · verify on EDGAR →
On May 5, 2026, Theriva Biologics, Inc., a Nevada corporation (the “Company”), issued a press release that included financial information for its quarter ended March 31, 2026.
The company announced its first quarter 2026 financial results through a press release. The 8-K itself does not contain the actual financial figures, which are in the attached press release exhibit. This is a standard earnings announcement filing.
Event · Item 9.01 — Financial Statements and Exhibits
Theriva Biologics filed an 8-K referencing a press release dated May 5, 2026; no material event details disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Press Release issued by Theriva Biologics, Inc., dated May 5, 2026.
The 8-K references a press release dated May 5, 2026, but does not disclose the content or subject matter of that release within the filing body. Without the actual press release text, the nature and materiality of the disclosed event cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify